$1.40 EPS Expected for CVS Health (CVS) This Quarter

Analysts predict that CVS Health (NYSE:CVS) will post earnings per share of $1.40 for the current quarter, according to Zacks Investment Research. Seventeen analysts have provided estimates for CVS Health’s earnings. The highest EPS estimate is $1.48 and the lowest is $1.13. CVS Health posted earnings per share of $1.17 during the same quarter last year, which would indicate a positive year-over-year growth rate of 19.7%. The company is scheduled to report its next earnings results before the market opens on Wednesday, May 2nd.

According to Zacks, analysts expect that CVS Health will report full year earnings of $6.30 per share for the current year, with EPS estimates ranging from $5.99 to $7.04. For the next fiscal year, analysts forecast that the company will report earnings of $6.73 per share, with EPS estimates ranging from $5.80 to $7.96. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that follow CVS Health.

How to Become a New Pot Stock Millionaire

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.88 by $0.04. CVS Health had a return on equity of 17.21% and a net margin of 3.58%. The business had revenue of $48.39 billion during the quarter, compared to analyst estimates of $47.54 billion. During the same period in the prior year, the company earned $1.71 earnings per share. CVS Health’s revenue was up 5.3% compared to the same quarter last year.

CVS has been the subject of several research reports. Mizuho set a $95.00 price objective on CVS Health and gave the company a “buy” rating in a report on Wednesday, January 24th. SunTrust Banks increased their price objective on CVS Health to $90.00 and gave the company a “buy” rating in a report on Friday, January 5th. Needham & Company LLC increased their price objective on CVS Health from $85.00 to $88.00 and gave the company a “buy” rating in a report on Tuesday, January 2nd. Tigress Financial reissued a “buy” rating on shares of CVS Health in a report on Tuesday, December 26th. Finally, Royal Bank of Canada set a $89.00 target price on CVS Health and gave the stock a “buy” rating in a research report on Thursday, February 8th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the stock. CVS Health currently has an average rating of “Buy” and a consensus price target of $86.65.

NYSE CVS traded up $0.95 on Thursday, hitting $67.05. 8,151,690 shares of the stock traded hands, compared to its average volume of 8,665,403. CVS Health has a 12 month low of $60.14 and a 12 month high of $84.00. The firm has a market cap of $64,351.77, a price-to-earnings ratio of 11.35, a price-to-earnings-growth ratio of 1.05 and a beta of 1.05. The company has a current ratio of 1.02, a quick ratio of 0.52 and a debt-to-equity ratio of 0.59.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 3rd. Investors of record on Monday, April 23rd will be given a $0.50 dividend. The ex-dividend date of this dividend is Friday, April 20th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.98%. CVS Health’s dividend payout ratio (DPR) is presently 33.90%.

In related news, EVP Helena Foulkes sold 19,965 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $71.04, for a total value of $1,418,313.60. Following the sale, the executive vice president now owns 65,072 shares in the company, valued at $4,622,714.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.61% of the company’s stock.

Several hedge funds have recently modified their holdings of CVS. Livforsakringsbolaget Skandia Omsesidigt increased its stake in CVS Health by 17.9% in the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 77,859 shares of the pharmacy operator’s stock valued at $5,645,000 after acquiring an additional 11,800 shares during the last quarter. Checchi Capital Advisers LLC increased its stake in CVS Health by 14.5% in the fourth quarter. Checchi Capital Advisers LLC now owns 9,063 shares of the pharmacy operator’s stock valued at $657,000 after acquiring an additional 1,150 shares during the last quarter. Prudential Financial Inc. increased its stake in CVS Health by 13.1% in the third quarter. Prudential Financial Inc. now owns 3,332,567 shares of the pharmacy operator’s stock valued at $271,004,000 after acquiring an additional 386,036 shares during the last quarter. Ameriprise Financial Inc. increased its stake in CVS Health by 30.2% in the third quarter. Ameriprise Financial Inc. now owns 7,977,370 shares of the pharmacy operator’s stock valued at $648,683,000 after acquiring an additional 1,849,593 shares during the last quarter. Finally, PGGM Investments increased its stake in CVS Health by 15.7% in the third quarter. PGGM Investments now owns 1,270,407 shares of the pharmacy operator’s stock valued at $103,309,000 after acquiring an additional 172,368 shares during the last quarter. Institutional investors own 83.97% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was first posted by registrarjournal.com and is owned by of registrarjournal.com. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://registrarjournal.com/2018/04/17/1-40-eps-expected-for-cvs-health-cvs-this-quarter.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.

Get a free copy of the Zacks research report on CVS Health (CVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply